BIVDA's half year Market Audit Report has been published
BIVDA’s IVD Market Audit Report has been published for the first half of 2020. The report contains revenue data inputted from twenty-seven companies which has been consolidated into a detailed report on the market size and growth, from totals down to assay level. The text includes for the first data submitted from ThermoFisher Scientific for their Microbiology products. This serves to enhance the coverage of the market which exceeds 95% of the total IVD market excluding Glucose self-tests.
Some key findings of the report include a snapshot of the substantial impact of COVID-19 pandemic on the carrying out of non-COVID diagnostic tests. These have been hit by the suspension of treatments and diagnostic efforts during the first wave of the COVID-19 pandemic beginning this year. Although the total market grew by 2.5%, revenues from General Chemistry, Hormones and Tumour Marker tests were reduced by 10 to 15% in the period (and this impact reflects only 3 months of ‘lockdown’ from the half year). Some test revenues were reduced by over 90%, while others increased by as much or more, and revenues from Coronavirus testing became one of the largest categories from negligible levels in 2019.
The BIVDA Market Audit is the most accurate and reliable source of data on the UK IVD market available by far, and participation is open to any UK IVD supplier at no cost if a member of BIVDA. Help in data submission, analysis and interpretation is available from BIVDA, and there is now also a website which allows access to data and generation of customised reports for participants. Please contact John Bagshaw, BIVDA Board member and Director of JAB Associates, for more information on the report and the data gathering approach undertaken in its composition.